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BACKGROUND:	  	  Periodontal	  disease	  has	  been	  investigated	  as	  a	  link	  to	  conditions	  like	  Diabetes	  Mellitus,	  Cardiovascular	   Disease	   (CVD),	   Pre-­‐Term	   Birth,	   as	   well	   as	   numerous	   chronic	  inflammatory	  diseases.	  Chronic	  Kidney	  Disease	   (CKD)	  has	  been	   linked	  with	  Diabetes	  Mellitus,	  Cardiovascular	  Disease	  and	  early	  mortality.	  	  Alone	  and	  combined,	  Periodontal	  disease	   and	   Chronic	   Kidney	   Disease	   affect	  millions	   of	   people	   and	   carry	   large	   public	  health	   implications.	   	   For	   this	   reason	   much	   research	   has	   been	   developed	   upon	  treatment	  modalities,	  local	  and	  systemic	  manifestations,	  prevalence,	  and	  risk	  factors	  of	  them	   both.	   	   The	   purpose	   of	   this	   study	   is	   to	   assess	   the	   effectiveness	   of	   non-­‐surgical	  periodontal	  therapy	  in	  CKD	  with	  periodontitis.	  	  
	  
Epidemiology	  of	  Periodontal	  Diseases:	  
	  Periodontal	  disease	   is	  an	   immune-­‐inflammatory	  disease	  caused	  by	  the	  host	  response	  to	  a	  bacterial	   insult	   in	   the	  periodontium	  (27).	   It	   is	   characterized	  by	  a	  chronic,	  gram-­‐negative	   infection	   initiated	   in	   the	   gingiva	   and	   leading	   to	   destruction	   of	   supporting	  connective	   tissues	   and	   alveolar	   bone.	   The	   host	   responds	   to	   the	   microbial/LPS	  challenge,	   with	   an	   abnormally	   high	   inflammatory	   response	   with	   increased	   levels	   of	  pro-­‐inflammatory	   cytokines	   like	   IL-­‐1,	   IL-­‐6	   and	   TNF-­‐α.	   These	   mediators	   promote	  activation	  of	  the	  acute	  phase	  reactants	  resulting	  in	  elevated	  serum	  levels	  of	  C-­‐reactive	  proteins	  (28).	  	  The	   National	   Health	   and	   Nutrition	   Examination	   Survey	   (NHANES)	   (1999)	   survey	  included	  over	  25,000	  participants	  from	  89	  sites	  in	  50	  states	  to	  assess	  the	  prevalence	  of	  periodontal	   disease	   in	   the	   United	   States.	   Prevalence	   of	   Periodontal	   disease	   among	  dentate	  adults	  aged	  20-­‐64	  years	  was	  as	  follows	  (1):	  	  	  	  
Demographic	   Prevalence	  Non-­‐Hispanic	  White	   5.82%	  Non-­‐Hispanic	  Black	   16.81%	  Mexican	  American	   13.76%	  	  The	   method	   used	   in	   the	   NHANES	   1999,	   and	   1994	   survey	   was	   criticized	   for	  underestimating	   periodontitis	   prevalence	   by	   up	   to	   50%	   (2)	   due	   to	   partial	   mouth	  screening,	   lack	   of	   radiographic	   data,	   the	   definition	   of	   disease,	   and	   the	   lack	   of	  distinction	  for	  previous	  tooth	  loss.	  	  A	  more	  accurate	  assessment	  is	  in	  the	  range	  of	  47%	  (54).	  	  Eke	  used	  NHANES	  2010	  to	  assess	  the	  prevalence	  of	  mild,	  moderate,	  and	  severe	  
periodontitis.	   	   This	  was	  more	   accurate	   than	   the	  NHANES	  1999	  data	   set	   because	   full	  mouth	  probing	  at	  all	  six	  sites	  per	  tooth	  was	  employed.	  	  According	  to	  current	  guidelines	  47%	  of	   the	  population	  (64	  million	  people)	  have	  a	   form	  of	  periodontal	  disease.	   	  8.7%	  have	  mild	  disease,	  30%	  have	  moderate	  disease,	  and	  8.5%	  have	  severe	  disease.	  With	   regards	   to	   the	   prevalence	   of	   CP	   in	   a	   CKD	   population,	   Ioannidou	   and	   Swede	  (2011)	  published	  data	  showing	  an	  increased	  prevalence	  compared	  to	  the	  NHANES	  III	  data.	  	  Furthermore,	  they	  showed	  that	  there	  was	  a	  significant	  dose-­‐response	  association	  between	  the	  prevalence	  of	  moderate	  CP	  and	  CKD	  for	  Non-­‐Hispanic	  Blacks	  and	  Mexican	  Americans.	  	  In	  this	  way,	  Non-­‐Hispanic	  Blacks	  and	  Mexican	  Americans	  with	  CKD	  are	  30-­‐60%	  more	   likely	   to	  have	  moderate	  CP	   than	   those	  without.	   	  The	  prevalence	   is	   shown	  below:	  
Demographic	   Prevalence	  Non-­‐Hispanic	  White	   12.9%	  Non-­‐Hispanic	  Black	   38.9%	  Mexican	  American	   37.3%	  	  The	  natural	  progression	  of	  periodontitis	  has	  been	  clearly	  shown	  to	  lead	  to	  edentulism	  (3)	   and	   compromise	   patient’s	   quality	   of	   life.	   	   However,	   in	   terms	   of	   systemic	  consequences,	   periodontitis	   has	   been	   shown	   to	   decrease	   total	   antioxidant	   capacity	  compared	   to	   healthy	   controls	   (4).	   Given	   the	   established	   role	   for	   reactive	   oxygen	  species	   (ROS)	   in	   cardiovascular	   pathology	   as	   well	   as	   the	   recently	   established	   links	  between	   periodontal	   disease	   and	   cardiovascular	   disease,	   the	   reduced	   plasma	   total	  antioxidant	   capacity	   in	   periodontitis	   subjects	  warrants	   further	   investigation	   (4).	   	   To	  that	  end,	  Tamaki	  et	  al.	   (2010)	  has	  shown	  that	  patients	  with	  periodontitis	  had	  higher	  baseline	   oxidized	   LDL	   (a	   direct	   measure	   of	   oxidative	   stress)	   and	   C-­‐reactive	   protein	  
(CRP)	   levels	   compared	   to	   healthy	   matched	   controls.	   	   Additionally,	   Tamaki	   et	   al.	  showed	  that	  nonsurgical	  periodontal	  therapy	  in	  patients	  with	  periodontitis	  decreased	  oxidized	  LDL	  and	  CRP	  serum	  levels	  to	  the	  levels	  of	  the	  control	  baseline	  (5).	  	  	  	  
Non-­Surgical	  Periodontal	  Therapy:	  	  There	   are	   numerous	   studies	   documenting	   the	   changes	   seen	   following	   non-­‐surgical	  periodontal	   therapy	   (NST).	   	   The	   general	   consensus	   for	   outcomes	   of	   periodontal	  parameters	  is	  an	  increase	  in	  recession	  (approximately	  1mm),	  decrease	  in	  PD	  (1-­‐3mm),	  and	  a	  gain	  in	  CAL	  (1mm)	  (75).	  	  Additionally,	  there	  is	  a	  decrease	  in	  BoP	  and	  PS,	  but	  the	  ranges	   reported	   throughout	   the	   literature	   are	   less	   consistent.	   	   Effectively	   a	   25%	  decrease	   can	   be	   seen	   with	   oral	   hygiene	   instruction	   alone,	   but	   some	   studies	   show	  expected	  outcome	  for	  Bop	  and	  PS	  after	  NST	  to	  be	  less	  than	  20%	  (75).	  	  Shallow	  pockets	  (1-­‐3mm)	  tend	  to	  lose	  attachment,	  while	  deeper	  pockets	  (4mm	  and	  above)	  tend	  to	  gain	  attachment	   (75).	   	   4	   years	   post	   treatment,	   Pihlstrom	   showed	   on	   average	   a	   1mm	  attachment	  gain	   in	  site	   initially	  7mm	  or	  more,	  and	  a	  0.4mm	  attachment	  gain	   in	  sites	  that	  initially	  measured	  4-­‐6mm	  (83).	  	  	  Dental	  biofilm	  provides	  an	  environment	  for	  bacteria	  to	  populate	  and	  thrive	  while	  being	  protected	  from	  the	  host	  immune	  response.	  	  While	  not	  in	  the	  scope	  of	  this	  present	  study,	  bacterial	  alterations	  have	  been	  demonstrated	  following	  NST.	  	  Among	  other	  changes,	  the	  most	  notable	  is	  a	  decrease	  in	  the	  red	  complex	  bacteria	  as	  demonstrated	  by	  numerous	  authors	  (75,	  84).	  	  
	  
Chronic	  Kidney	  Disease:	  	  Under	  normal	  physiological	  conditions,	  the	  kidneys	  receive	  approximately	  25%	  of	  the	  cardiac	   output.	   	   The	   kidneys	   serve	   multiple	   functions:	   control	   of	   plasma	   acid	   base	  balance,	   regulation	   of	   fluid	   volume,	   synthesis	   of	   erythropoietin,	   excretion	   of	  nitrogenous	   and	   water	   soluble	   waste,	   metabolizing	   varied	   drugs,	   and	   long-­‐term	  control	   of	   blood	  pressure.	   	   The	   kidney’s	   ability	   to	   filter	   the	  blood	   is	  measure	  by	   the	  glomerular	  filtration	  rate	  (GFR).	  	  Chronic	  Kidney	  Disease	  (CKD)	  is	  chiefly	  defined	  as	  a	  persistently	   reduced	  GFR	   (53).	   In	  2005	  Levey	   et	   al.	   defined	  CKD	  as	   a	  GFR	  <60	   for	  3	  months	  or	  greater.	  	  The	  functional	  unit	  of	  the	  kidney	  is	  the	  nephron,	  and	  it	  is	  ultimately	  responsible	   for	   filtering	   the	   blood.	   	   As	   each	   unit	   is	   damaged,	   the	   kidney’s	   ability	   to	  filter	   the	   blood	   diminishes	   until	   ultimately,	   replacement	   therapy	   (dialysis)	   or	  transplant	   is	   necessary	   to	   maintain	   the	   patient’s	   life.	   	   Kidney	   function	   can	   most	  accurately	  be	  measured	  by	  a	  24-­‐hour	  urine	  collection	  (29).	  This	  method	  is	  not	  practical	  in	   many	   settings,	   and	   thus	  many	   different	   equations	   have	   been	   created	   in	   order	   to	  accurately	  estimate	  and	  assess	  kidney	  function.	  	  	  	  Given	  the	  definition	  of	  CKD	  given	  by	  Levey	  et	  al.,	  glomerular	  filtration	  rate	  (GFR)	  is	  the	  gold	   standard	  measure	  of	   a	  kidney’s	  ability	   to	   function.	   	  One	  of	   the	  most	  universally	  accepted	  equations	  to	  estimate	  GFR	  is	  the	  Modified	  Diet	  in	  Renal	  Disease	  (55):	  	  GFR	  =	  186.3	  x	  (serum	  creatinine-­‐SCR)	  1.154	  X	  (age	  in	  years)	   -­‐0.203	  X	  1.212	  (if	  patient	   is	  black)	  x	  0.742	  (if	  female)	  	  There	  are	  shortcomings	  to	  this	  GFR	  estimation	  however	  and	  in	  2009,	  Glassok	  called	  its	  accuracy	   into	  question	   (29).	   	  With	   estimated	  GFR	   (obtained	  by	  MDRD)	  at	   or	   greater	  
than	   60	   ml/min	   per	   1.73m2,	   the	   deviation	   compared	   to	   the	   measured	   GFR	   (urine	  collection)	  was	  greater	  than	  30%.	  	  However,	  below	  60	  ml/min	  per	  1.73m2	  the	  accuracy	  and	  precision	  was	  high	  independent	  of	  age,	  sex,	  race,	  diabetes,	   transplant	  status,	  and	  body	  mass	   index	  (31).	   	  Thus	  despite	  being	  an	  estimation,	  Glassok	  concluded	  that	   the	  MDRD	   equation	   is	   an	   appropriate	   and	   reasonably	   unbiased	   estimation	   of	   GFR.	   	   The	  table	  below	  presents	  the	  Chronic	  Kidney	  Disease	  stages	  based	  on	  the	  estimated	  GFR.	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  In	   2005,	   the	   National	   Institute	   of	   Diabetes	   and	   Digestive	   and	   Kidney	   Diseases	  estimated	  that	  by	  the	  year	  2030,	  more	  than	  2	  million	  people	  in	  the	  United	  States	  will	  need	   dialysis	   or	   transplantation	   for	   kidney	   failure	   (stage	   5).	   	   In	   2005,	   19	   million	  Americans	  were	  in	  the	  “early”	  stages	  of	  CKD	  (14).	  	  For	   end	   stage	   renal	   disease,	   dialysis	   and	   kidney	   transplantation	   are	   the	   only	   two	  treatment	   choices	   for	   kidney	   replacement	   therapy.	   	   Given	   the	   difficulties	   of	   kidney	  transplantation,	   dialysis	   has	   been	   important	   treatment	   choice.	   	   Dialysis	   was	   first	  described	   and	   used	   in	   1854	   to	   separate	   substances	   in	   aqueous	   solution	   based	   on	  different	   rates	  of	  diffusion	   through	  a	   semipermeable	  membrane	   [20].	  The	  procedure	  
Stage	   Description	  
GFR	  
(ml/min/1.73m2)	  1	   Kidney	  damage	  w/	  normal	  or	  high	  GFR	   ≥90	  2	   Kidney	  damage	  w/mildly	  low	  GFR	   60-­‐89	  3	   Moderate	  GFR	  decrease	   30-­‐59	  4	   Severe	  GFR	  decrease	   15-­‐29	  5	   Kidney	  Failure	  (End	  Stage	  Renal	  Disease)	   <15	  
can	   be	   accomplished	   by	   either	   peritoneal	   dialysis	   (PD)	   or	   hemodialysis	   (HD).	   In	  peritoneal	  dialysis	  (PD),	  a	  catheter	  is	  permanently	  inserted	  into	  the	  peritoneum	  (lining	  around	  abdominal	  contents)	  through	  the	  abdominal	  wall	  and	  sterile	  fluid	  is	  drained	  in	  and	  out	  a	  few	  times	  each	  day	  [21].	  Hemodialysis	  therapy	  (HD)	  is	  performed	  every	  two	  or	  three	  days,	  usually	  three	  or	  four	  hours	  each	  through	  a	  vascular	  access	  connected	  to	  the	   dialysis	   device.	   Vascular	   access	   is	   accomplished	   by	   surgically	   placing	   an	  arteriovenous	   (AV)	   fistula,	   a	   graft	   or	   a	   venous	   catheter.	   A	  well-­‐functioning	   vascular	  access	  is	  essential	  to	  provide	  efficient	  dialysis	  therapy	  [22].	  
 	  
	  
Oxidative	  Stress	  and	  CKD:	  	  Oxidative	  stress	  takes	  place	  when	  the	  production	  of	  oxidants	  exceeds	  local	  antioxidant	  capacity	  leading	  to	  tissue	  injury	  (12).	  	  This	  imbalance	  of	  reactive	  oxygen	  species	  (ROS)	  leads	   to	   damage	   of	   cell	   lipids,	   protein,	   and	   DNA,	   inhibiting	   normal	   function	   (14).	  	  Oxidative	   stress	   has	   been	   linked	   to	   systemic	   inflammation,	   onset	   of	   periodontal	  destruction,	  CKD,	  and	  CVD	  (12-­‐14).	  	  	  	  Free	   radicals	   are	  produced	  normally	  during	  daily	  metabolic	  processes.	   	  The	  electron	  transport	   chain	   involved	   in	   respiration	   within	   the	   inner	   membrane	   of	   the	  mitochondria	   is	   perhaps	   the	  most	   ubiquitous	   (44).	   	   In	   a	   single	   day,	   a	   single	   cell	   can	  generate	   between	   1	   to	   3	   billion	   ROS,	   most	   of	   which	   are	   cleared	   by	   antioxidants.	  	  Furthermore,	  free	  radicals	  are	  generated	  by	  neutrophils	  and	  macrophages	  during	  their	  respiratory	   bursts	   in	   an	   effort	   to	   kill	   bacteria	   (14).	   	   Additionally,	   there	   are	   extrinsic	  sources	  of	  radical	  formation:	  heat,	  trauma,	  ultrasound,	  ultraviolet	  light,	  ozone,	  smoking,	  exhaust	  fumes,	  radiation,	  infection,	  excessive	  exercise,	  and	  even	  some	  drugs	  (43).	  	  Directly,	   ROS	   have	   the	   ability	   to	   damage	  DNA,	   lipid	  membranes,	   promote	   apoptosis,	  and	  deplete	   antioxidant	   stores	   (10,12,32,	   35-­‐40).	   	   The	  unpaired	   electrons	   are	  highly	  oxidizing	   and	   can	   attack	   carbon	   bonds,	   changing	   the	   tertiary	   structure	   of	   proteins.	  	  These	  changes	  can	  disrupt	  function,	  lead	  to	  protein	  accumulation,	  and	  ultimately	  “age”	  the	  cell	  more	  rapidly	  (10).	  	  Indirectly,	  ROS	  damage	  cells	  by	  exerting	  effects	  on	  the	  DNA	  and	  creating	  alterations	  in	  cellular	  activity	  through	  genetic	  disregulation	  (49).	  	  	  
	  Chronic	   kidney	   disease	   is	   characterized	   by	   a	   state	   of	   chronic	   inflammation	   and	  oxidative	   stress	   that	   has	   been	   associated	   with	   high	   mortality	   rates	   (50).	   The	  progressive	   loss	   of	   kidney	   function	   results	   in	   the	   accumulation	  of	   uremic	   toxins	   like	  cysteine,	   and	   homocystiene.	   	   Secondary	   to	   this,	   uremia	   (as	   well	   as	   hemodialysis)	  causes	   an	   increase	   in	   inflammatory	   cytokines	   and	   oxidants	   (16).	   Cytokine	   induced	  inflammation	   is	   implicated	   in	   the	   malnutrition-­‐inflammation-­‐atherosclerosis	   (MIA)	  syndrome	  that	  is	  also	  associated	  with	  frequent	  hospitalization	  and	  high	  cardiovascular	  mortality	  rates	  in	  CKD	  patients	  (50).	  The	  MIA	  syndrome	  is	  defined	  by	  the	  interaction	  between	  increased	  pro-­‐inflammatory	  cytokine	  levels,	  malnutrition	  and	  atherosclerosis	  in	  CKD	  patients	  (50).	  Elevated	  levels	  of	  inflammatory	  markers	  such	  as	  CRP	  and	  IL-­‐6	  are	  known	  predictors	  of	  cardiovascular	  outcomes	   in	   the	  general	  population	  as	  well	  as	   in	  the	   CKD	   population	   (Rao	   et	   al.	   2004),	   where	   they	   are	   linked	   to	   hypoalbuminemia,	  malnutrition,	   erythropoietin	   resistance	   and	   increased	   mortality	   (51,	   52). There	   are	  many	  sequelae	  associated	  with	  CVD,	  but	   it	  has	  been	  shown	   that	   the	  accumulation	  of	  reactive	  oxygen	  species	  leads	  to	  damage	  of	  the	  endothelium.	  	  This	  endothelial	  damage	  regardless	  of	  genesis,	  is	  ultimately	  the	  pathogenesis	  of	  CVD. 	  Conditions,	   which	   promote	   or	   increase	   chronic	   inflammation	   and	   oxidative	   stress	  exacerbate	   the	   risk	   for	  CVD	   in	  CKD	  patients.	   	  Libetta	  et	   al.	   showed	   that	  greater	   than	  50%	  of	  CKD	  patients	  die	  from	  CVD,	  namely	  by	  CVA.	  In	  an	  effort	  to	  assess	  the	  CVD	  risk,	  Cheung	  et	  al.	  showed	  that	  a	  45	  year	  old	  CKD	  patient	  is	  100fold	  more	  likely	  to	  die	  from	  a	  CVA	  compared	   to	  an	  age,	   sex,	   lipid	  profile	  matched	  non-­‐CKD	  control.	  CKD	  patients	  
have	  lower	  antioxidant	  capacity	  and	  their	  condition	  further	  increases	  the	  ROS	  burden.	  	  In	  2002,	  Himmelfarb	  reported	  high	  correlation	  between	  CVD	  mortality	  and	  increased	  levels	  of	  oxidative	  stress	  (16).	  	  	  
	  
	  Uremic	   patients	   are	   characterized	   by	   an	   accumulation	   of	   waste	   products	   normally	  filtered	  out	  by	  the	  kidneys.	  Uremic	  oxidative	  stress	  is	  characterized	  biologically	  by	  an	  increase	   in	   lipid	   peroxidation	   products	   and	   reactive	   aldehyde	   groups	   as	   well	   as	   by	  increased	  retention	  of	  oxidized	  thiols	  (49).	   	  Thus,	  before	  dialysis	  is	  instituted,	  uremic	  patients	  are	  already	  experiencing	  high	  oxidative	  stress	  levels.	  	  	  	  A	   substantial	   body	   of	   evidence	   has	   accumulated	   to	   suggest	   that	  MPO	   is	   involved	   in	  inflammation	   and	   oxidative	   stress	   in	   patients	  with	   kidney	   disease	   (49).	   Catalytically	  active	  MPO	  can	  be	  released	  during	  the	  hemodialysis	  procedure,	  and	  3-­‐chlorotyrosine,	  an	   oxidative	   stress	   biomarker	   highly	   specific	   for	   MPO-­‐	   catalyzed	   oxidation	   through	  hypochlorous	  acid,	  has	  been	  demonstrated	  in	  the	  plasma	  proteins	  of	  dialysis	  patients	  but	  not	  in	  that	  of	  healthy	  subjects.	  	  Furthermore,	  important	  antioxidants	  such	  as	  Thiols,	  and	  Glutathione	  are	  both	  depleted	  in	  absolute	  concentration	  and	  hyporeactive	  due	  to	  oxidation	  by	  way	  of	  the	  cystiene	  waste	  present	  in	  dialysis	  patients	  (49).	  	  Studies	  demonstrate	   that	   there	   are	   significantly	   elevated	   serum	  concentrations	  of	  C-­‐reactive	   protein	   and	   F2-­‐isoprostane	   levels	   in	   hemodialysis	   patients	   compared	   with	  patients	   with	   normal	   kidney	   function	   (62).	   	   Handelman	   showed	   in	   a	   study	  with	   25	  ESRD	  on	  HD	  and	  23	  healthy	  controls	  that	  the	  average	  total	  esterified	  F2-­‐isoprostanes	  
in	  the	  ESRD	  patients	  was	  1.62	  vs.	  0.27	  ng/mL	  in	  controls	  (P	  =0.001),	  with	  no	  overlap	  between	  patients	  and	  controls.	  	  Interestingly,	  plasma	  F2-­‐isoprostanes	  in	  diabetic	  ESRD	  patients	  were	  similar	  to	  F2-­‐isoprostanes	  in	  patients	  with	  other	  causes	  for	  renal	  failure.	  	  In	   the	   13	  patients	   in	  whom	  Diabetes	  was	   responsible	   for	   ESRD,	   the	   F2-­‐isoprostanes	  measured	  1.53ng/mL.	  In	  the	  12	  other	  patients,	  ESRD	  was	  caused	  by	  hypertension	  and	  other	   causes;	   in	   these	   patients,	   F2-­‐isoprostanes	   were	   1.71ng/mL.	   	   This	   was	   not	  statistically	  significant	  between	  groups	  (63).	  	  	  Handelman	  also	  showed	  that	   in	  a	  subset	  of	  10	  ESRD	  patients	  who	  were	  re-­‐evaluated	  eight	   months	   after	   the	   initial	   measurement,	   plasma-­‐esterified	   F2-­‐isoprostanes	   were	  not	  altered	  by	  an	  individual	  dialysis	  session	  (63).	  	  This	  is	  an	  important	  documentation	  because	  it	  clarifies	  the	  ability	  for	  one	  to	  follow	  F2-­‐isoprostane	  trends	  over	  time	  as	  long	  as	   there	   are	   no	   changes	   to	   dialysis	   treatment.	   	   If	   the	   F2-­‐isoprostanes	   were	   not	   as	  consistent	  their	  usage	  as	  a	  biomarker	  would	  be	  more	  limited.	  	  	  Himmelfarb	  argues	  that	  the	  reduced	  bioavailability	  of	  NO	  and	  abundant	   formation	  of	  ROS	   within	   the	   vascular	   wall	   detected	   in	   uremic	   patients	   seem	   to	   be	   the	   key	  determinants	  of	  endothelial	  dysfunction	  (16).	  Thus,	  oxidative	  stress	  plays	  a	  key	  role	  in	  pathogenesis	   of	   atherosclerosis	   and	   CVD.	   This	   is	   particularly	   pertinent	   for	   CKD	  patients	  because	  CVD	   is	   the	   leading	  cause	  of	  death	  as	   they	  experience	  a	   significantly	  increased	   rate	   of	   atherosclerotic	   complications	   and	   prevalence	   of	   cardiovascular	  disease	  compared	  to	  normal	  controls	  (15).	  	  





















Oxidative	  Stress	  and	  Chronic	  Periodontitis:	  	  It	  is	  widely	  understood	  that	  ROS	  are	  produced	  in	  the	  periodontal	  lesion	  (32-­‐34).	  ROS	  can	   promote	   bone	   loss,	   directly	   through	   cellular	   injury	   and	   indirectly	   through	   gene	  transcription	   alterations	   (34-­‐42).	   	   ROS	   production	   is	   an	   essential	   protective	  mechanism	  against	  diseases	  (Tomofuji	  2009),	  and	  periodontitis	  is	  no	  different.	  Neutrophils	  and	  macrophages	  present	   in	   the	  periodontal	   lesion	  produce	  ROS	  via	   the	  oxidative	  burst,	  which	   is	   released	   into	   the	  extracellular	  environment.	   	  Unfortunately,	  ROS	  are	  not	  target-­‐specific,	  and	  subsequent	  damage	  to	  host	  tissue	  occurs,	  confirming	  the	  critical	  role	  the	  host	  plays	  in	  the	  pathogenesis	  of	  periodontitis.	  	  	  As	   mentioned	   before,	   oxidative	   stress	   is	   the	   consequence	   of	   imbalance	   between	  oxidants	  (ROS,	  Free	  Radicals,	  etc.)	  and	  antioxidants	  (Glutathione,	  Ascorbic	  Acid,	  etc.).	  	  	  In	   2001	   Ebersole	   showed	   that	   in	   deep	   periodontal	   lesions	   Treponema	   denticola	   (T.	  
denticola),	   Aggregatibacter	   actinomycetemcomitans	   (A.a)	   metabolize	   glutathione,	   a	  primary	   antioxidant	   to	   produce	   hydrogen	   sulfide	   (Ebersole	   2001)	   resulting	   to	  decrease	   levels	   of	   local	   antioxidants.	   	   Consequently,	   in	   periodontal	   lesion	   the	  mechanisms	   promoting	   oxidative	   stress	   include	   increasing	   oxidant	   production	   and	  decreasing	  antioxidants	  (40).	  	  	  	  This	  double-­‐pronged	  attack	  has	  been	  shown	  to	  affect	  more	   than	   just	   the	  periodontal	  lesion	   itself.	   	   Multiple	   authors	   have,	   clearly	   shown	   increases	   in	   systemic	   oxidative	  stress	   in	   periodontitis	   patients	   when	   compared	   to	   periodontally	   healthy	   controls.	  	  
D’Aiuto	   (2011)	   showed	   that	   patients	  with	   severe	   periodontitis	   had	   higher	   oxidative	  stress,	  and	  lower	  total	  anti-­‐oxidant	  capacity	  when	  compared	  to	  periodontally	  healthy	  controls.	   	   In	   the	  same	  study,	   the	  patients	  were	  corrected	   for	  all	   confounders	  such	  as	  age,	   gender,	   ethnicity,	   and	   lipid	   profiles,	   allowing	  direct	   comparison	  with	   regards	   to	  oxidative	  stress.	  	  Ultimately,	  patients	  with	  severe	  periodontitis	  had	  an	  odds	  ratio	  of	  3.6	  	  for	  having	  increased	  oxidative	  stress	  compared	  to	  periodontally	  healthy	  controls.	  	  In	   2009,	   Tamaki	   evaluated	   the	   systemic	   oxidative	   stress	   in	   a	   prospective	  interventional	  trial	   treating	  mild	  to	  moderate	  chronic	  periodontitis	  with	  non-­‐surgical	  therapy.	   	  19	  patients	  with	  PPD	  of	  4mm	  or	  greater	  on	  4	   teeth	  were	  given	  scaling	  and	  root	  planing	  as	  non-­‐surgical	  therapy	  with	  oral	  hygiene	  instructions,	  while	  19	  controls	  were	   given	   oral	   hygiene	   instruction	   only.	   At	   baseline,	   the	   two	   groups	   showed	  statistical	   difference	   in	   regards	   to	   BoP,	   PPD,	   CAL,	   and	   ROM	   levels.	   In	   patients	   with	  periodontitis,	   the	  plasma	  ROM	   level	  was	  positively	   correlated	  with	  PD,	   CAL,	   and	   the	  percentage	  of	  sites	  with	  BOP	  but	  not	  with	  plaque	  level.	  	  One	  month	  after	  therapy	  ROM	  levels	  were	  close	  to	  the	  periodontally	  healthy,	  age	  matched	  controls	  being	  reduced	  by	  approximately	  30%.	   	  Ultimately,	  the	  results	  showed	  that	  there	  was	  a	  dose	  dependant	  response	  with	   the	  decrease	   of	  Reactive	  Oxygen	  Metabolites	   (ROM)	   in	   regards	   to	   the	  decrease	  in	  BoP.	  	  	  Again,	   in	   2010	   Tamaki	   evaluated	   systemic	   oxidative	   stress	   in	   patients	   with	   chronic	  periodontitis.	  Blood	  samples	  were	   taken	   from	  all	  44	  patients	  and	  were	  evaluated	   for	  total	   antioxidant	   capacity	   (Ox-­‐INDEX),	   ROM,	   and	   oxidized	   LDL	   (oxLDL).	   	   At	   baseline	  
the	  periodontally	  involved	  patients	  were	  statistically	  different	  in	  regards	  to	  BoP,	  PPD,	  OxLDL,	   and	   Ox-­‐INDEX.	   	   1	   and	   2	  months	   after	   therapy	   clinical	   parameters	   showed	   a	  positive	   response,	   BoP	   decreased	   from	  30%	   to	   5%,	   percentage	   of	   sites	  with	   4-­‐6mm	  PPD	  decreased	  from	  20%	  to	  11%.	  	  Ox-­‐INDEX	  was	  positively	  correlated	  with	  decrease	  in	  BoP	  as	  well	  as	  a	  decrease	  in	  oxLDL.	  The	  levels	  after	  therapy	  did	  not	  reach	  the	  levels	  of	  the	  healthy	  controls	  but	  it	  did	  decrease	  by	  37%,	  more	  than	  previously	  reported	  by	  Montebugnoli	  in	  2005	  (47).	  	  BOP	  is	  a	  clinical	  parameter	  used	  to	  evaluate	  the	  level	  of	   inflammation	  present	  within	  the	  periodontal	   lesion,	   and	  as	   such	   is	   a	   surrogate	  marker	  of	   effectiveness	  of	   therapy	  (48).	   	   These	   studies	   by	   Tamaki	   have	   shown,	   in	   a	   prospective	   fashion,	   that	   treating	  periodontitis	  can	  positively	  affect	  systemic	  oxidative	  stress	  levels	  in	  otherwise	  healthy	  patients.	  	  Both	  studies	  showed	  sufficient	  changes	  in	  clinical	  parameters	  indicating	  that	  non-­‐surgical	   therapy	  was	   performed	  well.	   	   It	   is	   particularly	   interesting	   that	   Tamaki	  found,	   in	   both	   instances,	   that	  BoP	  was	   correlated	  with	   an	   improvement	   in	   oxidative	  stress.	   However,	   the	   way	   that	   the	   increased	   circulating	   ROS	   from	   the	   periodontal	  lesion	   affect	   general	   health	   in	   patients	   with	   periodontitis	   is	   still	   unclear.	   Beyond	  directly	  causing	  tissue	  damage	  oxidative	  stress	  can	  cause	  changes	  in	  gene	  expression	  that	  indirectly	  leads	  to	  tissue	  damage.	  Ekuni	  (2009)	  used	  a	  rat	  model	  to	  experimentally	  prove	   that	   oxidative	   stress	   caused	   by	   a	   periodontal	   lesion	   could	   have	   affects	   in	   the	  vasculature	   both	   directly,	   through	   tissue	   damage	   and	   indirectly	   through	   gene	  regulation.	  	  8	  animals	  had	  ligature	  induced	  for	  periodontitis	  for	  4	  weeks,	  while	  8	  were	  left	   untreated.	   	  Molars	   and	   aorta	  were	   resected	   from	  both	   experimental	   and	   control	  
groups	  to	  be	  evaluated	   for	  hexanoyl-­‐lysine,	  ROS	  and	   lipid	  deposits.	  Descending	  aorta	  samples	   in	   the	   experimental	   group	   showed	   lipid	   accumulation,	   with	   increased	  expression	   of	   ROS	   and	   oxidative	   stress-­‐related	   genes	   compared	   to	   normal	   controls.	  	  There	  was	   increased	  expression	  of	  hexanoyl-­‐lysine,	  ROS	  and	  oxidative	   stress-­‐related	  genes	  (including	  nitric	  oxide	  synthases	  2	  and	  3),	  whereas	  the	  superoxide	  dismutase	  1	  gene	   level	   was	   down	   regulated.	   	   These	   findings	   were	   unique	   to	   the	   experimental	  periodontal	   and	   aortic	   tissues.	   	   This	   model	   showed	   prospectively	   the	   induction	   of	  periodontitis	  leads	  to	  increased	  lipid	  peroxidation,	  a	  measure	  of	  oxidative	  stress,	  both	  locally	  and	  systemically	  emphasizing	  the	  common	  biologic	  link	  between	  periodontitis	  and	  atherosclerosis.	  	  	  
Diabetes	  As	  A	  Confounding	  Systemic	  Disease:	  
	  Diabetes	   mellitus	   (DM)	   encompasses	   a	   heterogeneous	   group	   of	   disorders	   with	   the	  common	  characteristic	  of	  altered	  glucose	  tolerance	  or	  impaired	  lipid	  and	  carbohydrate	  metabolism.	  	  DM	  develops	  from	  either	  a	  deficiency	  in	  insulin	  production	  (IDDM/Type	  1)	  or	  an	  impaired	  utilization	  of	  insulin	  (NIDDM/Type	  2).	  	  Numerous	  studies	  have	  corroborated	   the	   fact	   that	  DM	   II	  and	  CP	  have	  a	  bidirectional	  relationship	  (66).	   In	  1993	  a	  study	  by	  Ternoven,	  showed	  that	  well-­‐controlled	  diabetic	  subjects	  had	  2.5%	  of	  sites	  with	  probing	  depths	  ≥	  4	  mm	  compared	  to	  11.2%	  of	  sites	  in	  poorly	  controlled	  diabetic	  subjects	  (69).	  	  This	  indicated	  that	  poor	  diabetic	  control	  lead	  to	   a	  worsening	  periodontal	   condition	   in	   regards	   to	   clinical	   parameters.	   	   There	   are	   a	  number	   of	   biologic	   complications	   as	   to	  why	   this	  may	   be.	   	   Impairment	   of	   neutrophil	  function,	  either	  in	  chemotaxis,	  adherence,	  and	  phagocytosis	  have	  all	  been	  shown	  to	  be	  present	  in	  diabetic	  patients	  when	  compared	  to	  healthy	  controls	  (70).	  	  Neutrophils	  are	  the	  primary	  response	  cell	  in	  the	  acute	  periodontal	  lesion	  and	  their	  impairment	  has	  the	  obvious	  consequence	  of	  an	  impaired	  host	  response	  and	  thus	  more	  severe	  destruction.	  	  	  	  Besides	   the	   host	   defense,	   tissue	   healing	   is	   impaired	   as	   well	   in	   diabetics.	   	   The	  hyperglycemic	  state	  induces	  glycosylation	  of	  proteins,	  which	  can	  impair	  their	  function	  (71).	   	   The	   glycosylation	   of	   the	   basement	   membrane	   proteins	   has	   garnered	   much	  attention	   as	   it	   is	   the	   focus	   for	   the	   underlying	   susceptibility	   to	   CVD	   seen	   in	   diabetic	  patients	   (72).	   	   In	   regards	   to	   periodontal	   wound	   healing,	   the	   changes	   in	   vascular	  permeability	   have	   been	   hypothesized	   to	   impede	   oxygen	   diffusion,	   metabolic	   waste	  elimination,	   PMN	  migration,	   and	  diffusion	  of	   serum	   factors	   including	   antibodies	   (66,	  
71,	  72).	  	  Thus	  the	  changes	  in	  vascular	  anatomy	  due	  to	  glycosylation	  decrease	  immune	  function	   and	   impede	  healing.	   	  With	   all	   of	   this	   considered	   it	   is	   clear	   that	   periodontal	  status	  of	  a	  diabetic	  patient	  is	  different	  from	  a	  non-­‐diabetic.	  	  With	   regards	   to	   response	   to	   therapy,	   Tervonen	   et	   al	   showed	   a	   similar	   response	  between	  diabetic	  and	  non-­‐diabetic	   controls	   to	  non-­‐surgical	   therapy	   (73).	   	  This	   study	  had	  over	  75	  patients	  and	   the	   reevaluation	  was	  completed	  between	  3-­‐4	  months	  after	  therapy.	   	   He	   showed	   approximately	   a	   50%	   reduction	   of	   bleeding	   on	   probing,	   and	   a	  33%	   to	  50%	  reduction	   in	   the	  number	  of	  pockets	  with	  probing	  depths	  of	  4	   to	  5	  mm.	  	  Ultimately,	   there	  was	  no	   statistically	   significant	   difference	   in	   responses	  between	   the	  controlled	  diabetic	  and	  non-­‐diabetic	  individuals	  in	  the	  study.	  	  When	   looking	   at	   long-­‐term	   response	   to	   therapy,	   again	   there	   has	   been	   evidence	  showing	  that	  diabetic	  patients	  are	  able	  to	  respond	  like	  non-­‐diabetic	  patients.	  	  Lindhe	  et	  al.	  evaluated	  20	  diabetic	  and	  20	  non-­‐diabetic	  age,	  gender-­‐matched	  patients	  in	  regards	  to	  their	  response	  to	  non-­‐surgical	  therapy	  and	  then	  again	  after	  surgical	  therapy	  up	  to	  5	  years	   later	   (74).	   	   Re-­‐examinations	   regarding	   plaque,	   gingivitis,	   probing	   depth	   and	  probing	   attachment	   level	   were	   performed	   12,	   24,	   and	   60	  months	   after	   the	   baseline	  examination.	  	  Surgery	  was	  performed	  at	  sites	  with	  remaining	  5mm	  or	  greater	  probing	  depths	   with	   bleeding	   on	   probing	   after	   non-­‐surgical	   therapy.	   	   Interestingly,	   the	  frequency	  of	  sites	  that	  exhibited	  signs	  of	  recurrent	  disease	  was	  similar	  in	  the	  two	  study	  groups.	  
The	  findings	  from	  the	  examinations	  disclosed	  that	  diabetics	  and	  non-­‐diabetics,	  treated	  for	  moderately	  to	  advanced	  forms	  of	  periodontitis,	  during	  a	  subsequent	  5-­‐year	  period,	  were	  able	  to	  maintain	  healthy	  periodontal	  conditions.	  	  	  Although	  many	   studies	   evaluated	   the	   effect	   of	   SRP	   in	   subjects	  with	   DM	   II,	   only	   two	  studies	  were	  found	  which	  examined	  the	  outcomes	  of	  SRP	  in	  CKD	  patients	  (67,	  68).	  In	  2010	  Artese	  et	  al.	   (67),	  evaluated	  the	  response	  of	  21	  pre-­‐dialysis	  subjects	  with	  CP	  to	  SRP	   and	   compared	   that	   to	   19	   systemically	   healthy	   patients	   with	   CP.	   	   These	   groups	  were	   matched	   for	   gender,	   BMI,	   ethnicity,	   and	   smoking	   status.	   The	   CKD	   patients	  responded	  similarly	  to	  CP	  (only)	  patients.	  Specifically,	  a	  significant	  decrease	  in	  gingival	  bleeding,	  visual	  plaque,	  suppuration,	  BoP,	  PD,	  and	  AL	  with	  no	  difference	  between	  the	  groups	  was	   seen	   at	   3	  months	   post-­‐SRP.	   	   In	   addition,	   statistically	   increased	  GFR	  was	  found	  for	  both	  groups.	  A	  key	  distinction	  in	  this	  study	  is	  that	  the	  CKD	  subjects	  were	  in	  the	   pre-­‐dialysis	   stage.	   	   It	   is	   reasonable	   to	   theorize	   that	   these	   subjects	   were	   yet	   to	  develop	   the	   severe	   uremic	   state	   seen	   in	   dialysis	   patients,	   and	   thus	   were	   not	   fully	  compromised	  in	  regards	  to	  immune	  responses	  and	  wound	  healing.	  	  Unfortunately,	  this	  study	   did	   not	   include	   F2-­‐isoprostane	   measurements	   as	   an	   outcome.	   	   Thus	   while	  showing	  that	  we	  could	  expect	  clinical	  parameters	  to	  respond	  in	  regards	  to	  periodontal	  parameters	   and	   GFR,	   we	   don’t	   know	   have	   any	   further	   knowledge	   of	   the	   oxidative	  status.	  	  Theoretically	  this	  could	  be	  shown	  with	  oxidative	  status	  as	  well.	  	  	  	  	  The	   other	   study	   to	   investigate	   the	   response	   to	   NST	   for	   CKD	   was	   by	   Graziani	   et	   al.	  (2010).	   	  Like	  Artese,	   they	   focused	  on	  the	  renal	  parameter	  of	  GFR	  and	  they	  showed	  a	  
significant	   increase	   following	   NST.	   	   In	   regards	   to	   the	   periodontal	   parameters	   they	  showed	   a	   mean	   CAL	   gain	   of	   approximately	   1mm	  with	   a	   mean	   PD	   reduction	   of	   just	  under	  2mm.	  	  BoP	  lowered	  about	  50%	  and	  PS	  lowered,	  but	  still	  remained	  above	  50%.	  	  Furthermore,	   they	   report	   these	   results	   are	   consistent	   180	   days	   post	   therapy.	   	   As	  explained	  previously,	   these	  numbers	   are	   very	   consistent	  with	  what	   can	  be	   seen	   in	   a	  systemically	  healthy	  population.	   	   It	   should	  be	  noted	   that	   in	   this	   study	   there	  were	  no	  systemically	  healthy	  or	  intervention	  controls	  (81).	  





In	  this	  study,	  we	  hypothesize	  that	  CKD	  patients	  with	  CP	  will	  show	  a	  positive	  response	  to	  
non-­surgical	  periodontal	  therapy	  as	  compared	  to	  a	  control	  group	  of	  CKD	  with	  CP	  that	  
received	  only	  supragingival	  prophylaxis.	  	   	  Specific	  Aim:	  	  1)	  to	  compare	  the	  change	  of	  periodontal	  parameters	  in	  a	  within	  and	  between	  group	  analysis.	  2)	  to	  assess	  the	  predictors	  of	  periodontal	  outcomes	  in	  the	  test	  and	  control	  groups	  
	  
STUDY	  ELEMENTS:	  
	   Design:	  Single	  blind	  randomized	  controlled	   trial	   to	  evaluate	   the	  effect	  of	  periodontal	   therapy	  on	  serum	  inflammatory	  and	  oxidative	  stress	  markers	  in	  CKD	  subjects.	  	  Population:	  The	   study	   was	   approved	   by	   the	   Institutional	   Review	   Board	   (IRB)	   (#10-­‐092-­‐02).	  Patients	  were	  recruited	  from	  the	  University	  of	  Connecticut	  Dialysis	  Center	  (UCDC),	  the	  Newington	   Dialysis	   Center	   in	   Newington,	   Connecticut,	   Fresenius	   Dialysis	   Center	   in	  Forestville,	   Connecticut,	   the	   Springfield	  Dialysis	   center	   in	   Springfield,	  Massachusetts,	  Heritage	  Dialysis	  Center	  in	  Chicopee,	  Massachusetts	  The	  nephrologist	  in	  each	  dialysis	  unit	  presented	  the	  study	  to	  the	  potential	  participants.	  	  IRB	   approved	   prescreening	   forms	   were	   filled	   for	   each	   patient.	   	   Following	   this,	   the	  study	  coordinator	  had	  a	  meeting	  with	  each	  potential	  participant	  to	  explain	  and	  discuss	  the	  IRB-­‐approved	  consent	  form.	  	  In	  the	  session,	  the	  patient	  had	  the	  opportunity	  to	  ask	  questions	   to	   the	   study	   coordinator	   related	   to	   the	   study.	   If	   the	  patient	  was	  willing	   to	  participate	  in	  the	  study,	  informed	  consent	  for	  participation	  was	  obtained.	  The	  patients	  were	  explained	  that	  they	  had	  to	  participate	  in	  the	  study	  for	  approximately	  two	  months,	  which	   included	   the	   follow-­‐up	   time	   period.	   The	   study	   involved	   a	   total	   of	   five	   visits,	  which	   included	  consent	   forms,	  blood	  draws,	   treatment	  and	  follow	  up	  visits.	   	  Only	  for	  the	   dialysis	   patients	   in	   Massachusetts,	   visits	   2	   and	   3	   were	   combined	   into	   one	   visit.	  	  Additionally,	   the	  Massachusetts	  patients	  were	  recruited,	   treated,	  and	  re-­‐evaluated	  all	  at	  the	  dialysis	  unit	  in	  order	  to	  minimize	  attrition	  rates.	  	  
At	  enrollment,	   patients	  were	   then	   scheduled	   for	   a	   comprehensive	  periodontal	   exam;	  subsequently	  they	  were	  randomly	  assigned	  to	  the	  test	  (scaling	  and	  root	  planing)	  and	  control	  (oral	  prophylaxis)	  groups.	  	  Consequently	  patients	  were	  then	  scheduled	  for	  a	  2	  month	  follow	  up	  visit	  where	  the	  comprehensive	  periodontal	  examination	  was	  repeated	  and	  blood	  samples	  were	  taken	  to	  evaluate	  any	  change	  as	  a	  result	  of	   intervention.	   	  At	  the	   therapy	   and	   re-­‐evaluation	   visits	   patients	  were	   financially	   compensated	   for	   their	  time.	  
Inclusion	  criteria:	  	  1)	  A	  minimum	  of	  15	  teeth	  2)	  No	  history	  of	  use	  of	  antibiotic	  within	  the	  last	  month	  3)	  No	  history	  of	  periodontal	  treatment	  within	  the	  last	  year,	  and	  4)	   No	   history	   of	   vascular	   access	   infection	   or	   clotted	   access	   within	   the	   last	   month	  (Hemodialysis	  patients)	  	  
Exclusion	  criteria:	  1)	   Severe	   co-­‐morbid	   conditions	   likely	   to	   affect	   life	   expectancy	   within	   1	   year	   (for	  example,	  metastatic	  cancer)	  2)	  Dementia,	  Pregnancy	  or	  lactation	  3)	  Inability	  or	  unwillingness	  to	  follow	  the	  study	  protocol	  4)	  Smoking	  5)	  Inability	  to	  meet	  any	  of	  the	  inclusion	  criteria	  	  	  F2	  Isoprostane	  Quantification:	  Plasma	   F2-­‐isoprostanes	   were	   measured	   by	   gas	   chromatography/negative-­‐ion	  chemical	  ionization	  mass	  spectrometry	  as	  described	  by	  Morrow	  et	  al.(54)	  The	  assay	  is	  commercially	  available	  and	  it’s	  precision	  is	  +/-6%,	  with	  an	  accuracy	  of	  96%.	  Data	  are	  expressed	  in	  nanograms	  per	  milliliter	  (ng/mL).(56)	  	  Periodontal	  Data	  Collection:	  The	   patients	   received	   a	   full	   mouth	   periodontal	   examination,	   which	   includes	   clinical	  attachment	   level	   (CAL),	   pocket	   depth	   (PD),	   bleeding	   on	   probing	   (BOP),	   and	   plaque	  
score	   (PS)	   at	   six	   sites	   on	   all	   teeth	   (mesio-­‐buccal,	   buccal,	   disto-­‐buccal,	   disto-­‐lingual,	  lingual	  and	  mesio-­‐lingual).	  Probing	  depth	  (PD)	  was	  measured	  from	  gingival	  margin	  to	  the	   base	   of	   pocket	   at	   6	   sites	   per	   tooth	   on	   all	   teeth.	   Recession	   was	   measured	   with	  respect	  of	  the	  gingival	  margin	  position	  in	  relation	  to	  the	  cementoenamel	  junction	  at	  six	  sites	  per	   tooth.	  The	  averaged	  whole-­‐mouth	  number	  of	  periodontal	   lesions,	   the	   score	  for	  full-­‐	  mouth	  gingival	  bleeding	  on	  probing	  (the	  number	  of	  sites	  with	  gingival	  bleeding	  on	  probing	  divided	  by	  the	  total	  number	  of	  sites	  per	  mouth,	  multiplied	  by	  100),	  and	  the	  score	  for	  full-­‐mouth	  plaque	  (the	  number	  of	  sites	  with	  detectable	  supragingival	  dental	  plaque	   divided	   by	   the	   total	   number	   of	   sites	   per	   mouth,	   multiplied	   by	   100)	   were	  calculated	  for	  each	  patient.	  	  The	  criteria	  for	  periodontitis	  were:	  	  	  1. Minimum	  of	  1	  site	  with	  5mm	  or	  greater	  PD	  and	  2. Minimum	  of	  2	  sites	  with	  6mm	  or	  greater	  CAL.	  
• OR	   i. at	  least	  2	  interproximal	  sites	  with	  clinical	  attachment	  loss	  (CAL)	  ≥	  4	  mm	  not	  on	  the	  same	  tooth	  ii. at	  least	  2	  sites	  with	  probing	  depth	  (PD)	  ≥	  5	  mm	  not	  on	  the	  same	  tooth	   	  Systemic	  markers:	  Baseline	  medical	  and	  demographic	  data	  will	  be	  obtained	  at	  the	  start	  of	  intervention.	  	  This	  data	  will	  include	  diabetic	  status,	  albumin	  level,	  dialysis	  vintage,	  age,	  gender,	  and	  ethnicity.	  In	  addition,	  blood	  samples	  were	  drawn	  from	  the	  arterial	  end	  of	  the	  vascular	  access	  immediately	  prior	  to	  HD	  initiation	  for	  quantification	  of	  serum	  F2	  Isoprostane.	  The	  samples	  were	  spun	  immediately	  for	  10	  minutes	  in	  a	  centrifuge	  and	  kept	  on	  ice	  for	  transportation.	  
	  Blood	  samples	  were	  drawn	  from	  both	  treatment	  groups	  in	  the	  same	  fashion	  repeated	  in	  2	  months	  after	  baseline	  quantifying	  the	  above	  markers.	  Blood	  samples	  were	  drawn	  at	  baseline	  for	  the	  periodontally	  healthy	  patients	  prior	  to	  HD	  initiation	  and	  any	  oral	  manipulation.	  	  	  	  CKD	   patients	   enrolled	   with	   periodontitis	   were	   randomly	   assigned	   in	   two	   groups.	  	  Randomization	   was	   performed	   with	   the	   use	   of	   a	   computer-­‐generated	   software	   in	  random	   permuted	   blocks	   of	   randomly	   distributed	   varying	   sizes.	   The	   blocks	   were	  stratified	   in	   the	   test	   and	   control	   group.	   The	   study	   coordinator	   was	   responsible	   for	  enrolling	   and	   then	   randomly	   allocating	   the	   patients	   to	   test	   or	   control	   groups.	   All	  participants	  and	  study	  personnel,	  including	  the	  dentist	  rendering	  the	  treatment,	  were	  unaware	   of	   the	   study	   assignments	   until	   the	   day	   of	   the	   procedure.	   The	   provider	  assessing	   the	   final	   outcomes	   will	   be	   blinded	   to	   the	   treatment	   group	   in	   order	   to	  minimize	  bias.	  	  However,	  for	  the	  Massachusetts	  patients,	  the	  provider	  was	  not	  blinded	  at	  the	  time	  of	  re-­‐evaluation.	  	  	  	  	  	  	   	  	  
Intervention	  -­‐	  Test/Control:	  The	  test	  group	  received	  oral	  hygiene	  instructions	  as	  well	  as	  full	  mouth	  scaling	  and	  root	  planning	  with	  local	  anesthesia	  in	  two	  appointments.	  The	   control	   group	   received	   oral	   hygiene	   instructions	   and	   full	   mouth	   supragingival	  debridement	  (7).	  This	  type	  of	  therapy	  was	  shown	  to	  have	  no	  impact	  on	  serum	  markers	  (7).	   The	   control	   group	   received	   full	   mouth	   periodontal	   treatment	   at	   the	   end	   of	   2-­‐	  month	  follow-­‐up	  period.	  	  The	  subjects	  will	  be	  recalled	  at	  2	  months	  time	  point,	  as	  described	  before	  (5,	  6).	  At	  this	  point,	   the	  medical	  history	  will	  be	  updated.	  Additionally,	   subjects	   received	   full	  mouth	  periodontal	  examination	  by	  a	  blinded	  examiner.	  Also,	  blood	  samples	  were	  collected	  for	  the	  quantification	  of	  serum	  F2	  Isoprostane	  levels,	  prior	  to	  oral	  manipulations.	  	   Primary	  outcomes:	  The	  change	  of	  the	  clinical	  periodontal	  parameters	  from	  baseline	  to	  2	  months	  	  (PD,	  BOP,	  PS	  and	  CAL)	  will	  be	  measured	  to	  evaluate	  the	  effectiveness	  of	  periodontal	  treatment	  in	  this	  population.	  	   Secondary	  outcomes:	  Predictors	  of	  response	  to	  treatment	  as	  derived	  from	  a	  multivariate	  regression	  model.	  	  Data	  Analysis:	  All	  data	  sets	  were	  tested	  for	  normality	  using	  the	  Shapiro	  Wilk	  test.	  When	  data	  was	  parametric,	  we	  used	  the	  unpaired	  student	  t-­‐test.	  When	  the	  data	  was	  non-­‐parametric	  







RESULTS:	  	  Baseline	  Demographic	  Data:	  The	  charts	  of	  213	  end-­‐stage	  renal	  disease	  patients	  (ESRD)	  were	  screened	  and	  34	  were	  enrolled	  in	  the	  study.	  22	  HD	  patients	  ultimately	  completed	  the	  study.	  	  Of	  these	  patients,	  17	  had	  periodontal	  disease	  and	  5	  were	  periodontally	  healthy.	  	  	  The	  main	  reason	  for	  prescreening	  failure	  was	  co-­‐morbidities	  and/or	  failing	  health,	  71	  patients.	  	  Of	  the	  remaining	  108	  patients	  who	  failed	  screening	  the	  reasons	  were:	  having	  less	  than	  15	  teeth,	  38	  (35%),	  not	  being	  interested	  after	  learning	  about	  the	  study,	  32	  (32%),	  not	  being	  proficient	  in	  English,	  12	  (10%),	  smoking,	  10	  (5%).	  	  The	  patient	  recruitment	  flow	  chart	  is	  shown	  in	  Figure	  1.	  	   Figure	  1	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  screening	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38	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  than	  15	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   32	  Not	  interested	   12	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Subject	  mean	  age	  was	  59	  years	  (range	  44-­‐80)	  with	  a	  median	  dialysis	  vintage	  of	  36	  months	  (range	  5-­‐84	  months).	  70%	  of	  the	  subjects	  were	  male,	  65%	  of	  subjects	  self	  reported	  their	  race	  as	  white,	  18%	  as	  blacks	  and	  17%	  subjects	  as	  Hispanics.	  	  59%	  subjects	  had	  diabetes.	  	  	  More	  specifically,	   the	  mean	  age	   in	  the	  test	  and	  control	  groups	  was	  64±14	  and	  59±17	  y/o,	   respectively.	  56%	  of	   the	   test	   group	  was	   comprised	  of	  male	  patients,	  while	  87%	  were	  in	  the	  control	  group.	  Diabetes	  was	  67%	  of	  the	  test	  and	  50%	  of	  the	  control	  group.	  	  Mean	  tooth	  number	  was	  24	  ±4.5	  for	  both	  test	  and	  control	  groups.	   	   	  Thus,	  at	  baseline	  when	  comparing	  the	  demographic	  characteristics	  between	  the	  two	  groups,	  there	  were	  no	  statistically	  significant	  differences	  observed.	  	  Baseline	  Periodontal	  Data:	  We	  compared	  the	  periodontal	  parameters	  at	  baseline	  by	  using	  the	  Mann	  Whitney	  test	  and	  Independent	  t-­‐Test	  depending	  on	  the	  normality	  of	  the	  distribution	  as	  evaluated	  by	  the	   Shapiro-­‐Wilk	   test	   of	   normality.	   There	   was	   no	   statistically	   significant	   difference	  between	  the	  groups	  at	  baseline	  regarding	  PD,	  CAL,	  BoP,	  PS,	  and	  number	  of	  teeth	  (Table	  1).	   	   	  The	  distribution	  of	  gender,	  diabetes,	  ethnicity,	  albumin,	  and	  dialysis	  vintage	  was	  not	   significantly	   different	   between	   groups	   (Table	   2).	   	   The	   results	   and	   p-­‐values	   are	  presented	  in	  Tables	  1	  and	  2	  below:	  	  	   	  	  	  	  
	  	  	   	  	  	  	  	  Table	  1:	  Baseline	  Periodontal	  Data	  
Baseline	  Data	   Test	   Control	   p-­value	  Mean	  BoP	  (%)	   40	   28	   0.26	  Mean	  PS	  (%)	   72	   75	   0.39	  Mean	  CAL	  (mm)	   3.8	   3.4	   0.63	  Mean	  PD	  (mm)	   3.1	   2.8	   0.18	  %	  of	  sites	  PD	  >	  5mm	   11	   8	   0.92	  Mean	  Teeth	  Number	   24	   24	   0.88	  	  	  	  	   Table	  2:	  Baseline	  Demographic	  Data	  
Baseline	  Data	   Test	   Control	   p-­value	  Age	   64	   54	   0.21	  %Male	   55	   87	   0.15	  %	  Diabetes	  Mellitus	   67	   50	   0.49	  %	  White	   78	   50	   0.13	  %	  Hispanic	   0	   37	   0.13	  %	  Black	   22	   13	   0.12	  Albumin	  (g/dL)	   4.0	   4.1	   0.18	  Dialysis	  Vintage	   2.7	   3.4	   0.44	  	  	  	  	  
	   Within	  Group	  Analyses	  Test	  group:	  When	  comparing	  the	  periodontal	  data	  of	  the	  two	  time	  points,	  we	  found	  a	  statistically	  significant	   improvement	   for	   all	   parameters.	   	   Table	   3	   below	   shows	   the	   levels	   of	  significance	   reached.	   	   With	   this	   representation,	   it	   becomes	   clear	   that	   non-­‐surgical	  therapy	   was	   effective	   in	   improving	   the	   clinical	   parameters.	   	   BoP,	   PS,	   CAL,	   PD,	   and	  percentage	  of	  sites	  with	  PD	  >	  5mm	  were	  statistically	   lowered	  after	   intervention.	   	  No	  teeth	  were	  lost	  during	  this	  treatment	  phase.	   	  This	   is	  an	  expected	  outcome	  for	  scaling	  and	   root	   planing	   and	   corroborates	  with	   numerous	   authors	   (5,	   66,	   67,	   73,	   74).	   	   It	   is	  important	  to	  note	  that	  while	  PS	  did	  significantly	  decrease,	  the	  absolute	  post-­‐treatment	  score,	   45%	   is	   not	   a	   satisfactory	   outcome	   of	   non-­‐surgical	   periodontal	   treatment	   and	  certainly	  shows	  limited	  patient	  compliance	  (80).	  	   Table	  3:	  Within	  Group	  Analysis;	  Test	  Group	  
Re-­evaluation	   Baseline	   Post-­tx	   p-­value	  Mean	  BoP	  (%)	   41	   23	   0.02	  Mean	  PS	  (%)	   72	   45	   0.02	  Mean	  CAL	  (mm)	   3.8	   3.2	   0.01	  Mean	  PD	  (mm)	   3.1	   2.6	   0.01	  %	  of	  sites	  PD	  >	  5mm	  (%)	   11	   3.4	   0.01	  Mean	  Teeth	   24	   24 0.38	  	  	  	  
	   Control	  group:	  When	  comparing	  the	  periodontal	  data	  of	  the	  two	  time	  points,	  the	  only	  parameter	  that	  showed	   a	   statistically	   significant	   difference	  was	   BoP.	   	   PS	   did	   show	   a	   positive	   trend,	  however,	   it	  did	  not	  ultimately	  reach	  significance.	   	  The	  trend	  and	  change	  in	  these	  two	  parameters	   is	   expected	   due	   to	   all	   supragingival	   plaque	   deposits	   removal	   during	  prophylaxis.	   	   Regardless	   of	   reaching	   significance,	   a	   PS	   of	   50%	   is	   generally	   not	  considered	  acceptable	  for	  maintaining	  periodontal	  health.	  	  The	  data	  for	  pre-­‐	  and	  post-­‐therapy	  along	  with	  its	  significance	  is	  shown	  below	  in	  Table	  4.	  	  	   Table	  4:	  	  Within	  Group	  Analysis;	  Control	  Group	  
Re-­evaluation	   Baseline	   Post-­tx	   p-­value	  Mean	  BoP	  (%)	   28	   15	   0.02	  Mean	  PS	  (%)	   75	   50	   0.09	  Mean	  CAL	  (mm)	   3.4	   3.52	   0.26	  Mean	  PD	  (mm)	   2.8	   2.81	   0.84	  %	  of	  sites	  PD	  >	  5mm	  (%)	   8	   6	   0.59	  Mean	  Teeth	  	   24	   24	   0.35	  	   	  	  	  	  	  
	  Between	  Group	  Analysis:	  After	  intervention	  both	  test	  and	  control	  parameters	  were	  tested	  for	  normality	  prior	  to	  running	   statistics.	   	   Paired	   t-­‐test	  was	   run	   for	   parametric	   distribution	  while	  Wilcoxon	  Ranks	   Test	   was	   run	   for	   non-­‐parametric	   distribution.	   	   Two	   parameters	   reached	  significance	   after	   intervention	   between	   the	   test	   and	   control	   groups,	   Mean	   CAL	  (p=0.01)	   and	  Mean	   PD	   (p=0.04).	   	   The	   test	   group	   gained	   significantly	  more	   CAL	   and	  significantly	   decreased	   PD	   compared	   to	   control.	   	   Mean	   percentage	   of	   sites	   with	  PD>5mm	  did	  show	  a	  positive	  trend,	  but	  did	  not	  reach	  significance	  (p=0.16).	  	  Mean	  BoP,	  PS,	  and	  Teeth	  Number	  all	  did	  not	  reach	  significance,	  nor	  showed	  any	  trend	  to	  favor	  test	  or	   control.	   Evaluation	   of	   the	   clinical	   parameters	   showed	   an	   effective	   non-­‐surgical	  therapeutic	   intervention.	   	   Table	   5	   below	   shows	   the	   values	   of	   the	   test	   and	   control	  parameters	  after	  intervention.	  	   	  	  	  	  	  	   Table	  5:	  Reevaluation	  Data	  
Reevaluation	  Data	   Test	   Control	   p-­value	  Mean	  BoP	  (%)	   23	   15	   0.85	  Mean	  PS	  (%)	   45	   51	   0.94	  Mean	  CAL	  (mm)	   3.2	   3.52	   0.01	  Mean	  PD	  (mm)	   2.6	   2.82	   0.04	  %	  of	  sites	  PD	  >	  5mm	   3	   6	   0.16	  Mean	  Teeth	  Number	   24	   24	   1.0	  	  
	  Subsequently	   analysis	   was	   carried	   out	   comparing	   the	   values	   of	   changes	   within	   the	  groups.	   	   After	   testing	   for	   normality,	   the	   unpaired	   student	   t-­‐Test	   and	  Mann	  Whitney	  tests	  were	  used	  to	  compare	  the	  values	  of	  change	  between	  the	  Test	  and	  Control	  group.	  	  ΔPD	   and	  ΔCAL	   showed	   a	   significant	   difference	   between	   the	   test	   and	   control	   groups.	  This	   confirms	   the	   data	   shown	   in	   Table	   5,	   where	   ΔMean	   CAL	   and	   PD	   reached	  significance	   between	   the	   groups	   (p=0.01,	   p=0.04,	   respectively).	   All	   other	   changes	   in	  clinical	   parameters	   did	   not	   statistically	   change	   between	   the	   groups.	   	   Non-­‐surgical	  therapy	  therefore	  showed	  a	  significant	  decrease	  in	  PD	  and	  gain	  in	  CAL	  as	  compared	  to	  prophylaxis.	  	  The	  values	  and	  their	  levels	  of	  significance	  are	  shown	  in	  Table	  6.	  	   	  Table	  6:	  Reevaluation	  Data:	  Test	  v.	  Control	  
Re-­evaluation	   Test	   Control	   p-­value	  ΔMean	  BoP	  (%)	   -­‐17%	   -­‐14%	   0.85	  ΔMean	  PS	  (%)	   -­‐26%	   -­‐25%	   0.94	  ΔMean	  CAL	  (mm)	   -­‐0.6mm	   0.1mm	   0.01	  ΔMean	  PD	  (mm)	   -­‐0.5mm	   0.03mm	   0.04	  ΔMean	  PD	  >	  5mm	  (%)	   -­‐8%	   -­‐1%	   0.16	  ΔMean	  Teeth	  	   0	   0	   1.0	  	  	  The	   mean	   PD	   for	   the	   test	   group	   decreased	   (Δ=-­‐0.5mm)	   to	   a	   mean	   of	   2.6mm,	   but	  increased	  for	  the	  control	  group	  (Δ=0.05mm).	  This	  difference	  between	  groups	  was	  also	  statistically	   significant	   (p=0.04),	   see	  Fig.	  2.	   	  The	   test	  group	  showed	  an	  average	  ΔCAL	  gain	  of	  0.6mm,	  to	  a	  mean	  of	  3.2mm	  and	  this	  was	  statistically	  significant	  as	  compared	  to	  
both	   pre-­‐therapy	   and	   the	   control	   group	   (p=0.011,	   p=.01	   respectively),	   see	   Fig	   3.	  	  Additionally	  we	  ran	  a	  Pearson	  Correlation	  to	  substantiate	  these	  descriptive	  statistics.	  	  	  Mean	  ΔCAL	  was	   highly	   significant	   (p=0.01),	   and	  Mean	  ΔPD	   trended	   (p=0.06).	   	   ΔBoP	  reached	  significant	  differences	   for	  both	   test	  and	  control	   (p=.02,	  p=.015,	  respectively)	  post	   intervention.	   	   However,	   the	   difference	   between	   the	   two	   groups	   did	   not	   meet	  statistical	   significance	   (p=0.85).	   	   The	   significant	   decrease	   in	   the	   pocket	   depth	   and	  increase	   in	   clinical	   attachment	   levels	   present	   in	   the	   test	   group	   alone	   confirms	   the	  efficacy	  of	  the	  non-­‐surgical	  therapy	  in	  this	  medically	  compromised	  population.	  	  	  	  	  Figure	  2.	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  Figure.	  4	  
	  	  Albumin,	  a	  surrogate	  marker	  of	  HD	  control,	  was	  positively	  correlated	  with	  Mean	  PD	  (r=0.5,	  p=0.04)	  and	  Mean	  CAL	  change	  	  (r=	  0.53,	  p=.0.03).	  	  This	  parallel’s	  the	  concept	  seen	  with	  DM	  whereas	  better	  control	  usually	  leads	  to	  more	  beneficial	  outcomes	  to	  therapy	  compared	  to	  poorly	  controlled	  subjects.	  	  No	  subjects	  were	  below	  3.7g/dL	  in	  our	  population,	  thus	  they	  would	  generally	  be	  considered	  adequately	  controlled.	  	  Our	  results	  show	  that	  better	  HD	  control,	  as	  demonstrated	  by	  higher	  albumin,	  leads	  to	  statistical	  change	  in	  Mean	  PD	  (Figure	  5)	  and	  CAL	  change	  (Figure	  6).	  	  	  
Figure	  5.	  
	  	  Figure	  6.	  
	  	  
The	  change	  in	  percentage	  of	  sites	  with	  PD>5mm	  had	  a	  statistical	  correlation	  with	  many	  variables.	   	  This	  was	  fitting	  as	  PD>5	  is	  an	  important	  parameter.	   	  One	  can	  assume	  that	  with	   no	   sites	   at	   5mm	  or	  more	   PD,	   the	   patient	   is	   a	   controlled	   subject	  with	   no	   active	  disease.	  	   	  Change	  in	  percentage	  of	  sites	  with	  PD>5mm	  was	  negatively	  correlated	  with	  Mean	  PD	   (r=-­‐0.8,	  p	  =0.0001),	  Mean	  BoP	   (r=-­‐0.51,	  p=0.036),	   and	  Mean	  PD>5mm	  (r=-­‐0.93,	   p=0.0001)	   at	   baseline.	   	   Change	   in	   percentage	   of	   sites	   with	   PD>5mm	   was	  positively	   correlated	   with	   the	   change	   of	   Mean	   PD	   (r=0.87,	   p=0.0001),	   Mean	   CAL	  (r=0.75,	  p=0.001),	  Mean	  BoP	  (r=0.5,	  p=0.037)	  at	  re-­‐evaluation.	  
DISCUSSION:	  The	  goal	  of	  non-­‐surgical	  periodontal	  therapy	  is	  the	  removal	  of	  etiologic	  factors	  in	  order	  to	   achieve	   reduction	   of	   pocket	   depth	   and	   gain	   of	   attachment.	   	   When	   this	   goal	   is	  achieved,	   therapy	   is	   considered	   to	   be	   effective.	   	   PD	   is	   considered	   as	   an	   indicator	   of	  existing	   periodontitis,	   whereas	   attachment	   loss	   represents	   cumulative	   past	   and	  present	  disease	  activity	  (12).	  	  Thus	  regaining	  attachment	  and	  decreasing	  pocket	  depth	  are	   main	   therapeutic	   goals	   when	   treating	   periodontal	   disease.	   	   Supragingival	  debridement	  or	  prophylaxis	  has	  been	  shown	  to	  not	  improve	  clinical	  attachment	  levels	  as	  compared	   to	  scaling	  and	  root	  planing	  (57).	   	  However,	  previous	   investigators	  have	  found	  that	  supragingival	  debridement	  does	  help	  to	  address	  marginal	  tissue	  health	  with	  decrease	  in	  BoP	  and	  PS	  (75).	  	  This	  trial	  has	  shown	  that	  non-­‐surgical	  periodontal	  therapy	  can	  be	  a	  safe	  and	  effective	  method	  in	  decreasing	  pocket	  depth	  and	  increasing	  clinical	  attachment	  for	  CKD	  patients.	  	  Interestingly,	   there	   were	   no	   adverse	   events	   during	   any	   treatments	   and	   all	   patients	  tolerated	   treatment	   and	   post-­‐operative	   healing	   without	   complication,	   although	   CKD	  and	  DM	  patients	  are	  at	  higher	  risk	  for	  infections	  (70,	  72,	  73).	  	  However,	  this	  has	  yet	  to	  be	   understood	   and	   fundamentally	   articulated	   in	   literature.	   	   It	   is	   known	   that	   non-­‐surgical	   therapy	   and	   supragingival	   prophylaxis	   both	   induce	   a	   transient	   bacteremia	  (76).	   	  Non-­‐surgical	  therapy	  induces	  bacteremia	  approximately	  40%	  of	  the	  time	  while	  prophylaxis	   (which	   includes	   flossing)	   induces	   it	   30%	   of	   the	   time	   (76).	   	   The	  investigation	  used	  30	  patients	  with	  CP	  and	  no	  systemic	  disease.	  	  In	  our	  study	  over	  50%	  of	  the	  CKD	  patients	  had	  DM,	  confirming	  immunosuppression.	  Despite	  this,	  none	  of	  the	  
population	   reported	   acute	   onset	   of	   illness	   of	   complications	   of	   any	   kind	   after	   either	  therapy.	  	  Furthermore,	  none	  of	  the	  patients	  were	  given	  antibiotic	  prophylaxis	  to	  guard	  against	  such	  a	  bacteremia	  and	  still	  there	  were	  no	  reported	  or	  recorded	  adverse	  events.	  	  Scaling	   and	   root	   planing	   has	   been	   shown	   to	   reduce	   PD,	   gain	   CAL,	   and	   remove	  subgingival	  deposits	   (57-­‐62).	   	  Decrease	   in	  PD	  has	  been	   in	   the	  range	  of	  1-­‐3mm	  and	  a	  gain	   of	   CAL	   of	   approximately	   1mm	   (57-­‐62).	   	   Generally,	   deeper	   initial	   PD	   showed	  greater	   reduction	   in	   PD	   and	   gain	   in	   CAL	   compared	   to	   more	   shallow	   pockets.	  	  Prophylaxis,	  by	  comparison	  has	  been	  repeatedly	  shown	  to	  have	  a	  nominal	  affect	  of	  PD,	  CAL,	   and	  gingival	   indices	   (57,	  58).	   	  Generally,	   as	   a	   result	  of	  non-­‐surgical	  periodontal	  therapy,	  we	   can	  expect	   at	  most	   a	  0.5mm	  decrease	   in	  PD,	  no	  gain	   in	  CAL,	   and	  a	  25%	  decrease	  in	  bleeding	  on	  probing	  (57-­‐59).	  	  After	   non-­‐surgical	   periodontal	   therapy	   we	   gained	   0.6mm	   of	   CAL	   and	   decreased	   PD	  0.5mm.	  	  This	  has	  not	  reached	  the	  expectations	  of	  previous	  authors.	  	  However,	  given	  the	  complex	  medical	  profile	  of	  CKD	  patients,	  we	  did	  not	  anticipate	  to	  reach	  or	  to	  achieve	  the	   end	   points	   that	   have	   been	   observed	   in	   systemically	   healthy	   subjects.	   	   It	   is	  important	  to	  note	  that	  these	  numbers	  are	  average	  values.	  	  So	  while	  0.5mm	  may	  not	  be	  clinically	   significant,	   we	   can	   see	   from	   the	   decrease	   in	   PD	   more	   than	   5mm	   that	   the	  therapy	  is	  still	  effective.	  	  It	  has	  been	  shown	  that	  deeper	  pockets	  tend	  to	  respond	  more	  favorably	  to	  non-­‐surgical	  therapy	  (75).	  	  In	  this	  way,	  the	  CKD	  population,	  despite	  their	  systemic	  complications,	   responded	  parallel	   to	   the	  healthy	  population.	   	  This	   response	  has	  also	  been	  shown	  with	  DM	  patients	  (74).	  	  	  
	  What	   is	   implied	   with	   this	   information	   is	   that	   these	   patients	   still	   require	   further	  treatment	  as	  there	  are	  still	  pocket	  depths	  remaining	  at	  5mm.	  	  To	  that	  end,	  Lindhe	  has	  shown	   that	   well	   controlled	   diabetics	   are	   capable	   of	   maintaining	   stable	   clinical	  attachment	   level	   after	   surgical	   periodontal	   therapy.	   	   However,	   with	   such	   a	   high	  remaining	  PS,	  further	  intervention	  is	  not	  warranted	  (80).	  	  A	   positive	   correlation	  was	   found	  with	   albumin	   value	   and	   the	  mean	   PD	   Change	   and	  mean	  CAL	   change.	   	   It	   is	   generally	   accepted	   that	   albumin	   levels	   are	   to	  be	  kept	   above	  3.7g/dL	   in	   CKD	   patients	   on	   HD	   (77).	   	   Within	   reason,	   higher	   albumin	   levels	   are	   an	  indicator	  of	  better	  control	  in	  HD	  therapy,	  whereas	  hypoalbuminemia	  is	  correlated	  with	  higher	  morbidity	   and	  mortality	   (56,	   78).	   	   Change	   in	   PD	   and	   CAL	   are	   two	   important	  clinical	   parameters	   to	   see	   effectiveness	   of	   therapy.	   	   The	   results	   infer	   that	   better	  HD	  control	   correlates	   with	   greater	   change	   in	   PD	   and	   CAL,	   meaning	   better	   response	   to	  therapy.	  	  The	  change	  in	  percentage	  of	  sites	  with	  PD>5mm	  had	  a	  statistical	  correlation	  with	  many	  variables.	  	  PD>5	  is	  an	  important	  parameter,	  because	  one	  can	  assume	  that	  with	  no	  sites	  at	  5mm	  or	  more	  PD,	  the	  patient	   is	  a	  controlled	  subject	  with	  no	  active	  disease.	   	   	  Most	  periodontal	  therapy	  is	  aimed	  at	  not	  just	  decreasing	  pocket	  depth,	  but	  also	  decreasing	  the	  pockets	  to	  less	  than	  five	  millimeters	  (27,	  74,	  75).	  	  A	  five	  millimeter	  pocket	  is	  the	  cut	  off	   point	   by	  which	   therapy	   is	   either	   considered	   complete,	   or	   if	  more	   intervention	   is	  required	  (74).	  	  The	  Change	  in	  PD>5mm	  was	  negatively	  correlated	  with	  Mean	  PD,	  BoP	  
and	  percentage	  of	  sites	  with	  PD>5mm	  at	  baseline.	  	  The	  negative	  correlation	  with	  Mean	  PD	  corroborates	  with	  classic	  literature	  showing	  that	  shallow	  pockets	  do	  not	  decrease	  in	  depth	  as	  much	  as	  deep	  pockets	  (78).	  	  The	  negative	  correlation	  with	  BoP	  hasn’t	  been	  described	   previously,	   but	   a	   plausible	   biologic	   explanation	   is	   that	   a	   subject	   with	   a	  baseline	  higher	  mean	  BoP	  may	  be	  more	  susceptible	  to	  the	  plaque	  burden.	  	  At	  first	  the	  negative	  correlation	  with	  mean	  PD>5mm	  at	  baseline	  was	  a	  quandary.	  	  However,	  when	  looking	   at	   how	   the	   data	  was	   collected	   an	   explanation	   came.	   	   All	   PD	   above	   5mm	  are	  grouped	  together.	  	  It	  is	  generally	  understood	  that	  an	  8mm	  pocket	  will	  not	  respond	  to	  therapy	  by	  decreasing	  to	  4mm	  or	  less.	   	  Thus	  when	  understanding	  that	  a	  subject	  with	  many	  PD>5mm	  may	  in	  turn	  have	  numerous	  7-­‐9mm	  pockets,	  and	  these	  pockets	  cannot	  expect	  to	  be	  reduced	  to	  a	  4mm	  pocket.	  	  It	  is	  reasonable	  then	  to	  understand	  that	  this	  is	  the	  reason	  for	  the	  negative	  correlation.	  	  This	  is	  particularly	  poignant	  in	  this	  population	  because	  we	  have	  shown	  that	  the	  gain	  in	  CAL	  and	  reduction	  in	  PD	  following	  NST	  is	  of	  a	  lesser	  magnitude	  compared	  to	  the	  historical	  data.	  	  Mean	  PD,	  CAL,	  and	  BoP	  change	  all	  correlated	  positively	  with	  the	  change	  of	  PD>5mm.	  	  This	   evidence	   is	   consistent	   with	   previous	   reports.	   	   Deeper	   pockets	   have	   greater	  reduction	   in	   PD	   and	   greater	   gain	   in	   CAL	   (74,	   78).	   	   Decrease	   in	   BoP	   is	   an	   expected	  outcome	  of	  non-­‐surgical	  therapy	  (75).	  	  In	  our	  study	  this	  provides	  further	  evidence	  that	  the	  benefits	  of	  non-­‐surgical	  periodontal	  therapy	  seen	  in	  a	  CKD	  population	  will	  parallel	  what	  is	  to	  be	  expected	  in	  a	  healthy	  population.	  	  
Prophylaxis	   corroborated	   with	   what	   has	   been	   reported.	   	   There	   was	   approximately	  25%	  decrease	   in	  bleeding	  on	  probing.	   	  There	  was	  a	  small	   increase	   in	  PD,	  and	   loss	   in	  CAL,	   although	  both	  were	  not	   clinically	  or	   statistically	   significant.	   	  This	   contrast	   from	  the	  non-­‐surgical	  therapy	  is	  well	  documented	  and	  thus	  was	  expected	  (75).	  	  Another	   interesting	   finding	   was	   the	   statistically	   significant	   BoP	   reduction	   in	   both	  groups,	   did	   not	   significantly	   correlate	   with	   the	   changes	   in	   PS	   for	   the	   control	   group	  (p=0.09).	   	  As	  both	  groups	   received	   the	  same,	   standardized	  oral	  hygiene	   instructions,	  and	  had	   the	   same	  baseline	   plaque	   score	   and	   teeth	  numbers,	  we	  naturally	   presumed	  that	  they	  would	  equally	  improve.	  	  PS	  did	  trend	  positively,	  though,	  and	  ultimately	  it	  did	  decrease	  the	  same	  magnitude	  in	  both	  groups.	  	  Although	  not	  statistically	  significant,	  the	  gender	   difference	   between	   groups	   could	   explain	   these	   differences.	   	   It	   has	   been	  contested	   in	   the	   literature	   that	  men	   tend	   to	   have	   less	   compliance	  with	   oral	   hygiene	  (58).	   	   Perhaps	   in	   this	   population,	   the	  males	   did	   practice	   less	   oral	   hygiene,	   and	   this	  explains	  the	  discrepancy	  between	  the	  two	  groups.	  	  Bleeding	  on	  probing	  decreased	  after	  treatment	  for	  both	  test	  and	  control;	  however	  the	  difference	  was	  not	  significant	  between	  the	  two	  groups.	  	  Plaque	  score	  and	  bleeding	  on	  probing	  typically	  parallel	  each	  other	  and	  are	  surrogate	  markers	  for	  patient	  compliance.	  	  Prophylaxis	  eliminates	  the	  supragingival	  plaque	  leading	  to	  a	  healthier	  marginal	  gingiva,	  however	  this	  is	  also	  accomplished	  during	  scaling	  and	  root	  planing.	  	  While	  plaque	  score	  did	   not	   reach	   significance,	   it	   did	   trend	   positively	   and	   decreased	   (in	   absolute	   value)	  similarly	  to	  the	  test	  group.	  	  
	  Normally,	  PS	  is	  used	  as	  a	  surrogate	  indicator	  for	  patient	  compliance.	  	  While	  it	  was	  not	  recorded,	  the	  general	  accumulation	  was	  severe	  and	  it	  became	  clear	  that	  home	  care	  was	  not	  given	  tremendous	  priority.	  Oral	  hygiene	  instruction	  was	  given	  to	  each	  patient	  and	  the	  importance	  of	  home	  care	  was	  stressed.	  	  However,	  lack	  of	  compliance	  characterizes	  individuals	   with	   chronic	   conditions	   such	   as	   CKD,	   DM	   etc	   (79).	   Hence,	   lack	   of	  compliance	  in	  this	  population	  was	  not	  surprising.	  	  Furthermore	  a	  positive	  correlation	  was	  found	  between	  dialysis	  vintage	  and	  PS.	   	  The	  longer	  a	  CKD	  patient	  was	  on	  HD	  the	  higher	  the	  PS	  would	  be.	   	  This	   further	  corroborates	  what	  has	  been	  found	  in	   literature	  that	  subject	  with	  chronic	  illnesses	  tend	  to	  become	  less	  compliant	  over	  time	  (75,	  79).	  	  Generally,	   BoP	   follows	   PS	   because	   bleeding	   is	   a	   consequence	   of	   the	   bacterial	   insult.	  BOP	  is	  an	  indicator	  of	  gingival	  inflammation	  and	  active	  disease	  (13).	  Despite	  a	  positive	  trend,	  without	   the	  mean	   PS	   dropping	   significantly	  we	   can	   hypothesize	   that	   the	   bio-­‐burden	   remained	   constant	   and	   the	   inflammatory	   insult	   did	   not	   change.	   PS	   for	   the	  control	  group	  did	  trend	  positively,	  but	  this	  result	  was	  not	  expected.	  	  One	  can	  theorize	  that	  BoP	  did	  significantly	  decreased	  after	  both	  test	  and	  control	   intervention,	  because	  perhaps	  both	  interventions	  were	  adequate	  in	  maintaining	  marginal	  tissue	  health	  (59).	  During	  the	  duration	  of	  this	  study,	  there	  was	  a	  very	  low	  enrollment	  rate	  (approximately	  15%).	  	  	  Approximately	  30%	  of	  the	  qualified	  population	  was	  uninterested	  in	  the	  study	  generally	  citing	  difficulty	  of	  transport,	  general	  health	  complications,	  and	  lack	  of	  time	  as	  the	   main	   reasons	   for	   not	   participating.	   	   This	   has	   been	   documented	   previously	   in	  literature	   where	   Sergeyeva	   et	   al.	   identified	   that	   physical	   limitations	   and	   fatigue	  
prevent	  this	  population	  from	  independent	  transportation,	  and	  these	  are	  major	  factors	  for	  low	  research	  study	  participation	  in	  this	  population	  (79).	  Despite	  our	  small	  available	  population,	  our	  15%	  enrollment	  rate	   is	  not	  much	  different	   from	  the	  12%	  enrollment	  rate	  seen	  by	  Sergeyeva,	  who	  screened	  6,276	  HD	  patients.	  	  	  	  The	  results	  show	  that	  amongst	  patients	  willing	  to	  enroll,	  the	  most	  common	  reason	  for	  disqualification	   was	   the	   lack	   of	   an	   adequate	   number	   of	   teeth,	   approximately	   35%.	  	  While	  there	  was	  no	  data	  kept	  on	  total	  tooth	  count	  per	  patient	  who	  failed	  pre-­‐screening,	  it	  was	  our	  observation	  that	  many	  patients	  were	  completely	  edentulous.	  	  Tooth	  loss	  can	  be	   from	   many	   reasons,	   however,	   the	   ultimate	   outcome	   of	   advanced	   periodontal	  disease	   is	   tooth	   loss.	   	   In	   a	   population	  with	   such	   heavy	   co-­‐morbidities	   and	   extensive	  systemic	  disease,	   one	   could	   reasonably	   theorize	   that	   lack	   of	   care,	   both	  personal	   and	  professional,	   coupled	   with	   a	   predisposition	   to	   periodontal	   disease	   could	   result	   in	  extensive	  tooth	  loss.	  	  Furthermore,	  there	  was	  a	  relatively	  large	  attrition	  and	  withdrawal	  rate,	  as	  35%	  of	  the	  patients	  withdrew	  (12	  of	  the	  34).	  	  Once	  enrolled,	  declining	  health	  and	  mortality	  were	  the	  most	   common	   reasons	   for	   attrition,	   33%	   (3	   patients	   passed	   away	   and	   1	   patient	  became	  too	  sick	  to	  travel).	  	  Factors	  such	  as	  socio-­‐economic	  status,	  transportation,	  and	  dialysis	   scheduling	   decrease	   a	   patient’s	   ability	   to	   participate	   in	   the	   RCT.	   	   When	  performing	  RCTs	   in	  medically	   compromised	  populations,	   one	   should	   be	   prepared	   to	  face	   issues	   of	   subject	   recruitment	   and	   retention	   affecting	   the	   study	   timeline	   and	  sample	  size	  achievement. 
 Limitations:	  One	   limitation	   of	   our	   study	   is	   the	   bias,	   which	   was	   introduced	   by	   the	   fact	   that	   for	  patients	   Massachusetts,	   the	   therapy	   was	   given	   in	   the	   dialysis	   unit,	   not	   in	   a	   dental	  operatory	  as	  done	  of	  the	  individuals	  recruited	  in	  Connecticut.	  	  Non-­‐surgical	  therapy	  is	  a	   tedious	   and	   time-­‐consuming	   labor	   (57).	   	   Specific	   operational	   factors	   could	   have	  interfered	  with	  the	  final	  treatment	  outcome.	  	  First	  and	  foremost,	  the	  absence	  of	  dental	  chair	  with	  a	  dental	  light,	  absence	  of	  dental	  assistant	  make	  it	  significantly	  more	  difficult	  to	   perform	   non-­‐surgical	   therapy.	   	   Furthermore,	   coordinating	   with	   the	   nurses	   and	  technicians	  during	  the	  HD	  session	  interrupts	  workflow.	  	  Lastly,	  patient	  factors	  such	  as	  patient	   anxiety	   and	  discomfort	   during	   their	   dialysis	   treatment	  due	   to	   fluctuations	   of	  electrolytes,	   glucose,	   and	   iron	   (79)	   could	   have	   interfered	  with	   rendering	   treatment.	  	  Cumulatively,	   all	   of	   these	   factors	   could	   have	   potentially	   interfered	   with	   treatment	  outcome.	  	  Another	   limitation	   is	   our	   sample	   size.	   	   With	   a	   population	   of	   17	   we	   cannot	   assume	  normal	   distribution	   for	   our	   data	   points.	   	   While	   tests	   for	   normality	   were	   employed	  prior	   to	   choosing	   a	   parametric	   or	   non-­‐parametric	   test,	   it	   is	   generally	   accepted	   that	  larger	  sample	  sizes	  give	  more	  reproducible	  results	  and	  thus	  more	  powerful	  statistics.	  	  Given	   the	   difficulties	   already	   mentioned	   regarding	   recruitment,	   the	   only	   way	   to	  address	  this	   is	  to	  extend	  the	  enrollment	  period	  and	  obtain	  enough	  patients	  to	  have	  a	  larger	  sample	  size.	  
	  
Future	  Directions:	  Upon	  obtaining	  the	  oxidative	  stress	  biomarker,	  F2-­‐isoprostane,	  analysis	  can	  be	  done	  to	  quantify	  the	  affect	  non-­‐surgical	  periodontal	  therapy	  has	  on	  systemic	  oxidative	  stress.	  	  F2-­‐isoprostane	  is	  an	  excellent	  biomarker	  to	  detect	  oxidative	  stress	  for	  a	  HD	  population	  because	   it	   has	   been	   shown	   to	   be	   consistent,	   not	   only	   through	   the	   day,	   but	   more	  importantly	  between	  HD	  sessions	  (from	  above).	  	  Using	  this	  information	  along	  with	  the	  five	   periodontally	   healthy	   CKD	   subjects	  we	  will	   be	   able	   to	   get	   a	   better	   sense	   of	   the	  background	  oxidative	  stress	  that	  CP	  contributes	  to	  these	  patients.	  	  
CONCLUSIONS:	  1. Non-­‐surgical	  therapy	  is	  a	  safe	  and	  effective	  treatment	  in	  the	  CKD	  population.	  2. Non-­‐surgical	  therapy	  results	   in	  significant	  decrease	  in	  PD,	  BoP,	  and	  PS	  as	  well	  as	  an	  increase	  in	  CAL	  however,	  not	   in	  the	  magnitude	  of	  a	  systemically	  healthy	  population.	  3. Change	  in	  PD>5mm	  correlates	  negatively	  with	  mean	  PD,	  BoP,	  and	  PD>5mm	  at	  baseline.	  4. Dialysis	  vintage	  correlates	  positively	  with	  baseline	  PS.	  5. Change	  in	  PD>5mm	  correlates	  positively	  with	  the	  change	  in	  mean	  PD,	  CAL,	  and	  BoP.	  6. Albumin	   values	   correlate	   positively	   with	   the	   change	   in	   mean	   PD	   and	   CAL	  implying	  that	  better	  HD	  control	  is	  correlated	  with	  better	  periodontal	  outcomes.	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